Zynerba Pharmaceuticals Stock Set to Soar on CBD News

The majority of covering analysts rate ZYNE a "strong buy"

Managing Editor
Feb 26, 2019 at 9:31 AM
facebook twitter linkedin

The shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) are soaring in electronic trading trading, last seen up 15.3%. Boosting the stock is news the drug name received a U.S. patent for its cannabidiol (CBD) treatment for Fragile X syndrome.

With today's expected surge, the stock is set to break back above the 120-day trendline -- a mark that has acted as a ceiling of resistance for the shares off and on since early 2018. ZYNE has added 70% year-to-date, through last night's close at $5.04.

While analysts have yet to react to the company's patent news, a majority of brokerages following the firm sported "strong buy" ratings coming into today. Plus, the stock's average 12-month price target stands at $16.40, a significant 225% premium to current levels.

Short sellers have targeted the stock, though. Short interest on ZYNE rose 8.3% during the past two reporting periods, and these bearish bets now represent a healthy 14.9% of the stock's total available float. At the equity's average daily pace of trading, it would take shorts less than two days to cover their bearish bets.


Special Offers from Schaeffer's Trading Partners